Coherus Oncology (CHRS) Inventory Average (2019 - 2026)

Coherus Oncology has disclosed Inventory Average across 8 years of filings, most recently posting $5.2 million for Q2 2026.

• In Q2 2026, Inventory Average rose 30.64% year-over-year to $5.2 million; the TTM figure through Jun 2026 stood at $5.2 million (up 30.64% YoY), while the FY2025 annual figure was $3.7 million, down 88.96% from the prior year.
• Inventory Average came in at $5.2 million for Q2 2026 at Coherus Oncology, up from $4.0 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $65.4 million in Q3 2023 to a low of $2.6 million in Q4 2025.
• Average Inventory Average over 5 years is $33.0 million, with a median of $33.8 million recorded in 2022.
• Year-over-year, Inventory Average surged 119.92% in 2023 and tumbled 94.02% in 2025.
• Over 5 years, Inventory Average stood at $33.3 million in 2022, then soared by 94.54% to $64.7 million in 2023, then tumbled by 59.93% to $25.9 million in 2024, then tumbled by 89.93% to $2.6 million in 2025, then surged by 101.0% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Inventory Average figures were $5.2 million in Q2 2026, $4.0 million in Q1 2026, and $2.6 million in Q4 2025.